BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $443,340 | -20.8% | 6,513 | -5.1% | 0.02% | -14.8% |
| Q2 2023 | $559,982 | +7.3% | 6,860 | -2.5% | 0.03% | 0.0% |
| Q1 2023 | $521,852 | -29.3% | 7,034 | -21.0% | 0.03% | -18.2% |
| Q4 2022 | $737,715 | +15.3% | 8,901 | +295.1% | 0.03% | +6.5% |
| Q3 2022 | $639,852 | -19.1% | 2,253 | -1.2% | 0.03% | -11.4% |
| Q2 2022 | $790,686 | -22.0% | 2,281 | -2.6% | 0.04% | -2.8% |
| Q1 2022 | $1,014,180 | -68.5% | 2,342 | -62.4% | 0.04% | -18.2% |
| Q4 2021 | $3,223,028 | +5.4% | 6,230 | -1.3% | 0.04% | 0.0% |
| Q3 2021 | $3,058,606 | -26.4% | 6,312 | -31.6% | 0.04% | -25.4% |
| Q2 2021 | $4,154,099 | +17.9% | 9,226 | +0.0% | 0.06% | +11.3% |
| Q1 2021 | $3,523,304 | +24.3% | 9,225 | +3.3% | 0.05% | +26.2% |
| Q4 2020 | $2,835,404 | +25.3% | 8,929 | -2.3% | 0.04% | +5.0% |
| Q3 2020 | $2,263,014 | -10.0% | 9,135 | -4.0% | 0.04% | -11.1% |
| Q2 2020 | $2,513,154 | +11.5% | 9,517 | -19.9% | 0.04% | -6.2% |
| Q1 2020 | $2,254,203 | -17.8% | 11,888 | -4.8% | 0.05% | +4.3% |
| Q4 2019 | $2,741,021 | +12.4% | 12,487 | +0.2% | 0.05% | +12.2% |
| Q3 2019 | $2,438,831 | -7.5% | 12,464 | -1.5% | 0.04% | -6.8% |
| Q2 2019 | $2,637,399 | +4.7% | 12,650 | -0.3% | 0.04% | -4.3% |
| Q1 2019 | $2,518,210 | +36.5% | 12,683 | -0.5% | 0.05% | +24.3% |
| Q4 2018 | $1,844,312 | -29.0% | 12,744 | +0.2% | 0.04% | -19.6% |
| Q3 2018 | $2,596,075 | -99.9% | 12,719 | -0.3% | 0.05% | +48.4% |
| Q2 2018 | $1,886,955,000 | +0.0% | 12,754 | +2.1% | 0.03% | +14.8% |
| Q1 2018 | $1,886,640,000 | +117228.4% | 12,491 | +0.7% | 0.03% | +28.6% |
| Q4 2017 | $1,608,000 | -63.8% | 12,410 | -66.3% | 0.02% | -25.0% |
| Q3 2017 | $4,448,000 | +3.0% | 36,791 | +0.1% | 0.03% | -6.7% |
| Q2 2017 | $4,320,000 | +17.3% | 36,765 | +1.5% | 0.03% | +15.4% |
| Q1 2017 | $3,683,000 | -1.4% | 36,228 | -0.2% | 0.03% | -3.7% |
| Q4 2016 | $3,734,000 | -6.6% | 36,316 | -0.6% | 0.03% | -6.9% |
| Q3 2016 | $4,000,000 | -3.1% | 36,526 | -0.3% | 0.03% | -6.5% |
| Q2 2016 | $4,130,000 | +27.0% | 36,619 | +6.4% | 0.03% | +24.0% |
| Q1 2016 | $3,252,000 | +8.0% | 34,408 | +2.8% | 0.02% | +8.7% |
| Q4 2015 | $3,011,000 | -2.1% | 33,456 | +0.6% | 0.02% | +4.5% |
| Q3 2015 | $3,076,000 | -6.9% | 33,270 | -0.8% | 0.02% | -4.3% |
| Q2 2015 | $3,303,000 | -1.5% | 33,543 | +0.3% | 0.02% | -8.0% |
| Q1 2015 | $3,355,000 | +12.5% | 33,457 | +3.7% | 0.02% | +19.0% |
| Q4 2014 | $2,982,000 | – | 32,275 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |